News | May 26, 2025
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
For the full year FY25, net profit soared 12x to Rs 345 crore
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
EBITDA for the period rose by 23.2% to Rs. 3,797 million
IOL Chemicals and Pharmaceuticals has posted net profit of Rs.101.07 crores for the Financial Year ended March 31, 2025
The CDMO upgrade represents a transformational step for Remedium Lifecare
EBITDA before special items decreases to €4.08 billion (7.4%)
Subscribe To Our Newsletter & Stay Updated
